Great Point Partners Lowered Its Sage Therapeutics (SAGE) Position; Carter William Co (CRI) Sentiment Is 1.28

December 7, 2017 - By Darrin Black

Great Point Partners Llc decreased Sage Therapeutics Inc (SAGE) stake by 18.73% reported in 2017Q2 SEC filing. Great Point Partners Llc sold 56,200 shares as Sage Therapeutics Inc (SAGE)’s stock rose 0.86%. The Great Point Partners Llc holds 243,800 shares with $19.42M value, down from 300,000 last quarter. Sage Therapeutics Inc now has $3.77B valuation. The stock increased 2.35% or $2.11 during the last trading session, reaching $91.9. About 570,678 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since December 7, 2016 and is uptrending. It has outperformed by 99.75% the S&P500.




CarterÂ’s, Inc., together with its subsidiaries, designs, sources, and markets branded childrenswear under the CarterÂ’s, Child of Mine, Just One You, Precious Firsts, OshKosh, and other brands. The company has market cap of $5.21 billion. The firm operates through five divisions: CarterÂ’s Retail, CarterÂ’s Wholesale, OshKosh Retail, OshKosh Wholesale, and International. It has a 21.19 P/E ratio. The Company’s CarterÂ’s products include baby products, such as bodysuits, pants, dresses, multi-piece sets, blankets, layette essentials, bibs, and booties; play clothes products comprising knit and woven cotton apparel; sleepwear products consisting of pajamas in cotton, fleece, and ploy-jersey; and other products, including bedding, outerwear, swimwear, footwear, socks, diaper bags, gift sets, toys, and hair accessories.

The stock increased 0.40% or $0.44 during the last trading session, reaching $110. About 352,234 shares traded. Carter's, Inc. (CRI) has declined 16.63% since December 7, 2016 and is downtrending. It has underperformed by 33.33% the S&P500.

Ratings analysis reveals 60% of Carter Holdings’s analysts are positive. Out of 5 Wall Street analysts rating Carter Holdings, 3 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $88.28 while the high is $95.0. The stock’s average target of $91.64 is -16.69% below today’s ($110) share price. CRI was included in 6 notes of analysts from September 27, 2016. CLSA initiated it with “Underperform” rating and $95.0 target in Thursday, September 29 report. Morgan Stanley initiated the stock with “Overweight” rating in Wednesday, January 25 report. The rating was upgraded by Piper Jaffray on Tuesday, February 14 to “Overweight”. Citigroup upgraded the stock to “Buy” rating in Monday, December 19 report. The stock of Carter's, Inc. (NYSE:CRI) earned “Market Perform” rating by Wells Fargo on Tuesday, September 27.

Pivot Point Capital Partners Llc holds 14.81% of its portfolio in Carter's, Inc. for 180,100 shares. Darsana Capital Partners Lp owns 1.60 million shares or 6.19% of their US portfolio. Moreover, Valinor Management L.P. has 3.35% invested in the company for 1.24 million shares. The Connecticut-based White Elm Capital Llc has invested 2.96% in the stock. Petrus Trust Company Lta, a Texas-based fund reported 105,508 shares.

Analysts await Carter's, Inc. (NYSE:CRI) to report earnings on February, 22. They expect $2.19 EPS, up 22.35% or $0.40 from last year’s $1.79 per share. CRI’s profit will be $103.65M for 12.56 P/E if the $2.19 EPS becomes a reality. After $1.70 actual EPS reported by Carter's, Inc. for the previous quarter, Wall Street now forecasts 28.82% EPS growth.

Investors sentiment decreased to 0.98 in Q2 2017. Its down 0.13, from 1.11 in 2017Q1. It dived, as 24 investors sold SAGE shares while 61 reduced holdings. 30 funds opened positions while 53 raised stakes. 37.20 million shares or 2.18% more from 36.41 million shares in 2017Q1 were reported. Moreover, Gam Hldg Ag has 0.09% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Atika Management Ltd Liability accumulated 7,000 shares. Brown Advisory holds 0% or 3,111 shares in its portfolio. Moreover, Point72 Asset Mngmt Ltd Partnership has 0.06% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 125,000 shares. Smith Asset Grp LP reported 0.02% stake. Pictet Asset Mngmt Ltd has 480,013 shares for 0.1% of their portfolio. Emerald Advisers Pa reported 182,804 shares. Fernwood Invest Management Lc has invested 0.47% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 1,702 were accumulated by Envestnet Asset Management. Tradewinds Ltd Liability Com reported 0.01% stake. Citadel Advisors Ltd Company stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Pioneer Incorporated has invested 0.04% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 22,312 were reported by Mirae Asset Glob Invs Limited. 50,000 were reported by Ghost Tree Limited Com. Fred Alger Management accumulated 9,009 shares or 0% of the stock.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on February, 22. They expect $-2.00 earnings per share, down 33.33% or $0.50 from last year’s $-1.5 per share. After $-1.97 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.52% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.